Trials testing a treatment · 7 studies
Something new is being tried here: a medicine, a regimen or a procedure. If you join, you receive either the treatment under study or the standard one, and the team follows you closely.
Relapsed chronic lymphocytic leukaemia or small lymphocytic lymphoma: pirtobrutinib
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The purpose of Part 2 of this study is to evaluate pirtobrutinib monotherapy in participants with treatment-naïve CLL/SLL with 17p deletions. Participation in Part 1 is expected to last approximately 3 years. Participation in Part 2 is expected to last up to 2 years.
For: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
5 centres: Fundeni Clinical Institute, București · Institutul Oncologic Cluj, Cluj-Napoca · Spitalul Clinic Municipal Filantropia Craiova, Craiova · and 2 more
Phase 2See the official record ↗NCT06588478
Original registry title
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Blood cancers: nemtabrutinib, a medicine under study
The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).
For: Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
4 centres: Centrul de Diagnostic si Tratament Oncologic Brasov, Brașov · Spitalul Clinic Colțea, București · Institutul Regional de Oncologie Iasi, Iași · and 1 more
Phase 2See the official record ↗NCT04728893
Original registry title
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Untreated diffuse large B-cell lymphoma: zilovertamab vedotin replacing vincristine in the classic regimen
The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
For: Diffuse Large B-Cell Lymphoma
4 centres: Centrul de Diagnostic si Tratament Oncologic Brasov, Brașov · Spitalul Clinic Colțea, București · Institutul Oncologic Cluj, Cluj-Napoca · and 1 more
Phase 3See the official record ↗NCT06717347
Original registry title
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Chronic lymphocytic leukaemia or small lymphocytic lymphoma: APG2575, a medicine under study
This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors
For: CLL/SLL
3 centres: București · Cluj-Napoca · Timișoara
Phase 3See the official record ↗NCT06104566
Original registry title
Global Trial in APG2575 for Patients With CLL/SLL
Relapsed chronic lymphocytic leukaemia or small lymphocytic lymphoma: BGB-16673 compared with pirtobrutinib
The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent Bruton tyrosine kinase inhibitor (cBTKi).
For: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
3 centres: Coltea Clinical Hospital, București · Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca, ClujNapoca · Institutul Regional de Oncologie Iasi, Iași
Phase 3See the official record ↗NCT06973187
Original registry title
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Relapsed or refractory diffuse large B-cell lymphoma: a therapeutic vaccine alongside pembrolizumab
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
For: Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
2 centres: Bucharest Oncology Institute "Prof.Dr.Al. Trestioreanu", București · The Oncology Institute "Prof. Dr. Ion Chiricuţă" I.O.C.H., Cluj-Napoca
Phase 2See the official record ↗NCT04920617
Original registry title
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Mature B-cell cancers: SGR-1505, a medicine under study
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
For: Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia
2 centres: ARENSIA Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti, București · ARENSIA Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca, Cluj-Napoca
Phase 1See the official record ↗NCT05544019
Original registry title
Study of SGR-1505 in Mature B-Cell Neoplasms
Observational studies · one study
You do NOT receive a new treatment here. You have your usual care, and researchers collect information about how it goes. Useful for people after you, but it does not change your own care.
Observational registry for newly diagnosed peripheral T-cell lymphoma
This study T-Cell Project 2.0 is based on the former International PTCL study designed by the International T-cell Non-Hodgkin's Lymphoma Study Group (T-Cell Project 1.0: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma) as a prospective collection of data to predict the prognosis of patients with the more frequent subtypes of PTCL. It is a prospective, longitudinal, international, observational study of patients with newly diagnosed peripheral T-cell lymphoma aiming to verify whether this prospective collection of data would allow achieving a more accurate information on T-cell lymphomas.
The study aims to better define the clinical relevance of the new WHO Classification, the role of FDG-PET in staging and response assessment, the prognosis of different entities, the genomic landscape of different subtypes, and to investigate on most optimal treatment strategies for these neoplasms in the real-world population as well as molecular markers and to explore the prognostic or predictive implications of them in PTCL.
The study aims to better define the clinical relevance of the new WHO Classification, the role of FDG-PET in staging and response assessment, the prognosis of different entities, the genomic landscape of different subtypes, and to investigate on most optimal treatment strategies for these neoplasms in the real-world population.
For: Peripheral T-Cell Lymphoma
One centre: Cluj Napoca_Ion Chiricuta Oncology Institute, Cluj-Napoca
Phase not statedSee the official record ↗NCT03964480
Original registry title
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.
Source: ClinicalTrials.gov, the public registry of the US National Library of Medicine. Data retrieved on 14 Sept 2026.
